Aptuit To Acquire EaglePicher Pharmaceutical Services
Aptuit, Inc. (Greenwich, CT) has agreed to acquire the assets and operations of EaglePicher Pharmaceutical Services (EPPS, Lenexa, KS) as part of Aptuit?s strategies to build capabilities in active pharmaceutical ingredient (API) development and drug substance manufacturing.
Greenwich, CT (Sept. 26)––Aptuit, Inc. (Greenwich, CT, www.aptuit.com) agreed to acquire the assets and operations of EaglePicher Pharmaceutical Services (EPPS, Lenexa, KS, www.eaglepicher.com) as part of Aptuit’s strategy to build capabilities in active pharmaceutical ingredient (API) development and drug substance manufacturing.
Aptuit will acquire EaglePicher’s facilities in Lenexa, Kansas and Harrisonville, Missouri and plans further investments. “We intend to make significant investments in our new API operation over the next 18 months to upgrade the EPPS Harrisonville facility, extend its range of capabilities, and improve its regulatory profile,” said Michael A. Griffith, CEO of Aptuit, in a company release. “Additionally, we will be building a first-class lab-based process-development and kilo-lab capability.”
The acquisition extends Aptuit’s capabilities to include API supply from post discovery to market. Following the acquisition, Aptuit will have 12 facilities globally, including a clinical trial distribution network of 27 supply depots. The acquisition is expected to close within 90 days.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
